Insider · CIK 0001757072
Kyle Carver
Files at EVMN (Evommune, Inc.). First filing Jun 1, 2026, latest Jun 1, 2026.
Kyle Carver files SEC Form 4 as CFO at EVMN (Evommune, Inc.). Since Jun 1, 2026, Kyle Carver has reported 0 open-market buys worth $0 and 1 open-market sell worth $415k, the latest filed on Jun 1, 2026.
A track record needs three past buys with six months of prices behind them; Kyle Carver has 0, so none is measured yet.
The newest scored trade: sold $415k of EVMN on May 28, 2026, filed Jun 1, 2026, scored 23 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $415k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EVMN: Evommune, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Evommune, Inc. | $415k 18,175 shares | -23% | +55% from low-26% from high |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | EVMN Evommune, Inc. | MOption exercise Common Stock10b5-1 | +15,000 | $2.99 | $45k | 77,510 | Jun 1, 2026 |
| May 28, 2026 | EVMN Evommune, Inc. | SOpen-market sale Common Stock10b5-1 | -18,175 | $22.84 | $415k | 59,335 | Jun 1, 2026 |
| May 28, 2026 | EVMN Evommune, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 96,731 | Jun 1, 2026 |
| Apr 16, 2026 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +98,946 | $0.00 | $0 | 98,946 | Apr 17, 2026 |
| Dec 9, 2025 | EVMN Evommune, Inc. | FTax withholding Common Stock | -13,290 | $17.84 | $237k | 62,510 | Dec 11, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Common Stock | +3,175 | - | - | 75,800 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series B Preferred Stockderivative | -25,000 | - | - | 0 | Nov 12, 2025 |
| Nov 5, 2025 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +279,408 | $0.00 | $0 | 279,408 | Nov 7, 2025 |
Questions about Kyle Carver
Answered from the filings on this page, as of the latest one.
Is Kyle Carver buying or selling?
In the last 12 months Kyle Carver reported 0 open-market buys worth $0 and 1 open-market sell worth $415k on SEC Form 4; the latest was sold $415k of EVMN on May 28, 2026. Grants, option exercises and tax withholding are not counted.
How did Kyle Carver's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kyle Carver has 0.
Where does Kyle Carver file Form 4?
Kyle Carver has filed Form 4 at EVMN (Evommune, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.